Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 16/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 1/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | BLK | P51451 | 1/20 | 1.00 |
| ▸ | BMX | P51813 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 1.00 |
| ▸ | TAOK2 | Q9UL54 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prn-1371 SCHEMBL16993012 | 1.00 | FGFR1 (1.00) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16993372 | 0.96 | FGFR1 (1.00) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16993276 | 0.95 | FGFR1 (1.00) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16993179 | 0.95 | FGFR1 (1.00) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| Prn-1371 SCHEMBL30089820 | 0.95 | FGFR1 (0.90) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| Prn-1371 SCHEMBL30089811 | 0.94 | FGFR1 (0.89) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL20434261 | 0.93 | FGFR1 (0.87) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL18522475 | 0.93 | FGFR1 (0.86) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16997097 | 0.92 | FGFR1 (1.00) | FGFR1FGFR2CSF1RLYNFGFR4 | |
| SCHEMBL16993193 | 0.92 | FGFR1 (0.86) | FGFR1FGFR2CSF1RLYNFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005813-A | Targeted treatment of cancers with deregulated fibroblast growth factor receptor signaling | 法码科思莫斯控股有限公司 | 2026-05-12 | — | — | CN | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | UNIV NEW YORK (US) | 2025-11-20 | — | — | US | claimed |
| EP-4543931-A2 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | New York University (US) | 2025-04-30 | — | — | EP | claimed |
| CN-119866347-A | Compositions and methods comprising antibodies conjugated to covalent peptide conjugates | 纽约大学 | 2025-04-22 | — | — | CN | claimed |
| US-20240408047-A1 | HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS FOR THE TREATMENT OF BLADDER CANCER | NIKANG THERAPEUTICS, INC. | 2024-12-12 | — | — | US | claimed |
| US-20240327928-A1 | METHOD FOR IDENTIFYING RESPONSIVENESS TO FIBROBLAST GROWTH FACTOR RECEPTOR 1 INHIBITOR THERAPY | UNIV KOELN (DE) | 2024-10-03 | — | — | US | claimed |
| EP-4423302-A2 | NOVEL KINASE FUSIONS DETECTED BY LIQUID BIOPSY | Foundation Medicine, Inc. (US) | 2024-09-04 | — | — | EP | claimed |
| EP-4419089-A1 | HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS FOR THE TREATMENT OF BLADDER CANCER | Nikang Therapeutics, Inc. (US) | 2024-08-28 | — | — | EP | claimed |
| CN-118414439-A | Novel kinase fusion by liquid biopsy | 基金会医学公司 | 2024-07-30 | — | — | CN | claimed |
| WO-2022174234-A2 | BIOMARKERS FOR CANCER TREATMENT | FOUNDATION MEDICINE, INC. (US) | 2022-08-18 | — | — | WO | claimed |
| EP-4041237-A1 | TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING | G1 Therapeutics, Inc. (US) | 2022-08-17 | — | — | EP | claimed |
| US-20220241275-A1 | TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING | PHARMACOSMOS HOLDING A/S (DK) | 2022-08-04 | — | — | US | claimed |
| US-20220233536-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | QED THERAPEUTICS, INC. | 2022-07-28 | — | — | US | claimed |
| CN-114761009-A | Targeted treatment of cancer with deregulated fibroblast growth factor receptor signaling | G1治疗公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2022125967-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | ERASCA, INC. (US) | 2022-06-16 | — | — | WO | claimed |
| WO-2022073994-A1 | LMP7-SELECTIVE INHIBITORS FOR THE TREATMENT OF BLOOD DISORDERS AND SOLID TUMORS | MERCK PATENT GMBH (DE) | 2022-04-14 | — | — | WO | claimed |
| EP-3976042-A2 | METHODS OF TREATING CHOLANGIOCARCINOMA | QED Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | claimed |
| CN-114144180-A | Method for treating bile duct cancer | QED医药股份有限公司 | 2022-03-04 | — | — | CN | claimed |
| WO-2020243273-A9 | METHODS OF TREATING CHOLANGIOCARCINOMA | QED THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408047-A1 | HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS FOR THE TREATMENT OF BLADDER CANCER | HIF1AN, HIF1A, EGLN2 | FGFR1 2056/4885FGFR2 791/4885CSF1R 3443/4885 |
| US-20220241275-A1 | TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885FGFR2 2/4885CSF1R 647/4885 |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | MICA, CD74, HLA-DRB1 | FGFR1 3437/4885FGFR2 2703/4885CSF1R 2844/4885 |
| US-20220233536-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | KRAS, SLC10A2, SLC10A1 | FGFR1 18/4885FGFR2 7/4885CSF1R 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.